INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 43h ago
House PTR3h ago
SEC 13F3h ago
Robinhood Chain3h ago

Most active filers · 30d

  1. 01Kurtz George0B / 220S220 trades$52.89M
  2. 02SPSaba Capital Management, L.P.77B / 19S · 11 late96 trades$25.89M
  3. 03SJSheena Jonathan0B / 57S57 trades$3.61M
  4. 04ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  5. 05AJAllaire Jeremy0B / 50S50 trades$4.26M
  6. 06Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  7. 07SLSpeiser Michael L0B / 35S35 trades$14.00M
  8. 08RARothblatt Martine A0B / 33S33 trades$5.50M
  9. 09RJRubinstein Julie0B / 32S32 trades$5.48M
  10. 10CECrimmins David Edward0B / 31S31 trades$723K

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 631 insiders$417K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 108 insiders$40.91M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  7. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  8. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M

Form 4 transactions

70,320 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
0
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M—
1,430 sh
Mar 11, 2026Mar 13, 2026
Page 1145 of 1758
← PrevNext →
traded Mar 11, 2026
+2d
SEC Form 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
7,998 sh
Mar 12, 2026Mar 13, 2026
traded Mar 12, 2026
+1dSEC Form 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
5,000 sh
Mar 12, 2026Mar 13, 2026
traded Mar 12, 2026
+1dSEC Form 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
8,332 sh
Mar 12, 2026Mar 13, 2026
traded Mar 12, 2026
+1dSEC Form 4

Evidence

0
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M—
2,405 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
KS
Kerr Michael SGeneral Counsel
QTWOQ2 Holdings, Inc.
Grant or award · 10b5-1 plan
A—
7,322 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$68K
7,998 sh
Mar 12, 2026Mar 13, 2026
traded Mar 12, 2026
+1dSEC Form 4

Evidence

0
KS
Kerr Michael SGeneral Counsel
QTWOQ2 Holdings, Inc.
Grant or award · 10b5-1 plan
A—
3,664 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M$16K
98 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M$21K
110 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M—
1,274 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
FM
Fong MorganGENERAL COUNSEL & SECRETARY
CARTMaplebear Inc.
Option exercise · 10b5-1 plan
M—
110.3K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M$223K
2,405 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
KS
Kerr Michael SGeneral Counsel
QTWOQ2 Holdings, Inc.
Grant or award · 10b5-1 plan
A—
7,322 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
12.5K sh
Mar 12, 2026Mar 13, 2026
traded Mar 12, 2026
+1dSEC Form 4

Evidence

0
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M—
1,729 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

43
HJ
Hill JaimePresident, Building Materials
AMRZAmrize Ltd
Open-market purchase
BUY$57K
1,000 sh
Mar 12, 2026Mar 12, 2026
traded Mar 12, 2026
+0dSEC Form 4

Evidence

40
RJ
Rinke Todd J.Senior Vice President
WMBWILLIAMS COMPANIES, INC.
Open-market sale
SELL$548K
7,364 sh
Mar 11, 2026Mar 12, 2026
traded Mar 11, 2026
+1dSEC Form 4

Evidence

38
CM
Colendich Katie MarieGC, Corporate Secretary
ASANAsana, Inc.
Open-market sale
SELL$54K
7,304 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

37
SC
Schoch Martin C.EVP of Supply Chain
BGSB&G Foods, Inc.
Open-market sale
SELL$61K
11.3K sh
Mar 12, 2026Mar 12, 2026
traded Mar 12, 2026
+0dSEC Form 4

Evidence

37
SK
Sykes KarenPRESIDENT, CMO DD'S DISCOUNTS
ROSTROSS STORES, INC.
Open-market sale
SELL$547K
2,556 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

33
PJ
Park JaehyunChief Financial Officer
OPBKOP Bancorp
Open-market sale
SELL$12K
958 sh
Mar 12, 2026Mar 12, 2026
traded Mar 12, 2026
+0dSEC Form 4

Evidence

28
ME
Mickels ErikChief Financial Officer
MKTWMARKETWISE, INC.
Open-market sale
SELL$51K
3,334 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

28
LI
Layton Kathleen I.Chief Legal Officer
OPRTOportun Financial Corp
Open-market sale
SELL$61K
12.4K sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

27
BR
Burson Andrea RichardsChief Human Resources Officer
NATLNCR Atleos Corp
Grant or award
A$865K
19.4K sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

25
SS
Sonne StephenCHIEF LEGAL OFFICER
PDYNPalladyne AI Corp.
Open-market sale
SELL$51K
6,802 sh
Mar 12, 2026Mar 12, 2026
traded Mar 12, 2026
+0dSEC Form 4

Evidence

25
TT
Thatcher TrevorCHIEF FINANCIAL OFFICER
PDYNPalladyne AI Corp.
Open-market sale
SELL$58K
7,649 sh
Mar 12, 2026Mar 12, 2026
traded Mar 12, 2026
+0dSEC Form 4

Evidence

24
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Other acquisition or disposition
J—
3,095 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

24
ME
Mickels ErikChief Financial Officer
MKTWMARKETWISE, INC.
Open-market sale
SELL$98K
6,666 sh
Mar 11, 2026Mar 12, 2026
traded Mar 11, 2026
+1dSEC Form 4

Evidence

23
WA
Wilkes AlexanderDirector, Chief Executive Officer
EYENational Vision Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$929K
35.0K sh
Mar 11, 2026Mar 12, 2026
traded Mar 11, 2026
+1dSEC Form 4

Evidence

23
SS
Sitaram SiddharthInterim PFO and PAO
DOCSDoximity, Inc.
Open-market sale · 10b5-1 plan
SELL$64K
2,282 sh
Feb 10, 2026Mar 12, 2026
traded Feb 10, 2026
+30dSEC Form 4

Evidence

23
NL
Nolf Aurelien Pierre LeonChief Financial Officer
NAVNNavan, Inc.
Grant or award
A—
97.4K sh
Mar 3, 2026Mar 12, 2026
traded Mar 3, 2026
+9dSEC Form 4

Evidence

23
HT
Hornfeck TraciChief Accounting Officer
NATLNCR Atleos Corp
Grant or award
A$400K
8,977 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

21
SH
Singh HarvinderEVP & PRESIDENT, INTERNATIONAL
IARTINTEGRA LIFESCIENCES HOLDINGS CORP
Grant or award
A—
60.9K sh
Mar 11, 2026Mar 12, 2026
traded Mar 11, 2026
+1dSEC Form 4

Evidence

21
HS
He Hank ShenghuaDirector
SFDSMITHFIELD FOODS INC
Grant or award
A—
208.7K sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

21
GH
Gonzalez HughGeneral Counsel
OFGOFG BANCORP
Option exercise
M—
667 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

21
DF
De Bosschere FabriceChief Accounting Officer
MMIMarcus & Millichap, Inc.
Option exercise
M—
600 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

21
KC
Kozlik ChristenChief Accounting Officer
ACELAccel Entertainment, Inc.
Option exercise
M—
4,798 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

21
WD
Watts Keller D.Chief Business Officer
SFDSMITHFIELD FOODS INC
Grant or award
A—
81.4K sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

21
GA
Gandhi AnandChief Financial Officer
EBEventbrite, Inc.
Disposition to issuer
D—
567.5K sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence